Free tool
FAERS Monitor: Enflonsia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761432 or its brand name (Enflonsia, Clesrovimab-Cfor). Reports on generic versions are filed under their own applications.
Reports
13
Serious
2
15% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event5
- extra dose administered2
- injection site pain2
- injection site swelling2
- product administered to patient of inappropriate age2
- pyrexia2
- respiratory syncytial virus infection2
- bacterial test positive1
- blood culture positive1
- influenza1
- injection site mass1
- medication error1
- product dose omission issue1
- rash1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bacterial test positive | 1 | 725.9 | 110.4 | 180 |
| blood culture positive | 1 | 540.0 | 82.1 | 134 |
| product administered to patient of inappropriate age | 2 | 532.1 | 148.7 | 596 |
| respiratory syncytial virus infection | 2 | 371.7 | 103.9 | 415 |
| extra dose administered | 2 | 79.9 | 22.3 | 87 |
| no adverse eventSignal | 5 | 44.6 | 22.4 | 173 |
| injection site mass | 1 | 43.8 | 6.7 | 10 |
| injection site swelling | 2 | 42.2 | 11.8 | 45 |
| medication error | 1 | 29.1 | 4.4 | 6 |
| influenza | 1 | 14.5 | 2.2 | 3 |
| injection site pain | 2 | 10.5 | 2.9 | 9 |
| pyrexia | 2 | 9.4 | 2.6 | 8 |
| product dose omission issue | 1 | 5.5 | 0.8 | 1 |
| rash | 1 | 3.7 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.